An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure.

An open-label dose escalation study to evaluate the safety of administration of nonviral stromal cell-derived factor-1 plasmid to treat symptomatic ischemic heart failure.

Penn Marc S; Mendelsohn Farrell O; Schaer Gary L; Sherman Warren; Farr Maryjane; Pastore Joseph; Rouy Didier; Clemens Ruth; Aras Rahul; Losordo Douglas W

Circulation research

2013

2013-03

RATIONALE: Preclinical studies indicate that adult stem cells induce tissue repair by activating endogenous stem cells through the stromal cell-derived factor-1:chemokine receptor type 4 axis. JVS-100 is a DNA plasmid encoding human stromal cell-derived factor-1. OBJECTIVE: We tested in a phase 1, open-label, dose-escalation study with 12 months of follow-up in subjects with ischemic cardiomyopathy to see if JVS-100 improves clinical parameters. METHODS AND RESULTS: Seventeen subjects with ischemic cardiomyopathy, New York Heart Association class III heart failure, with an ejection fraction

*Plasmids; Aged; Brain/blood; Chemokine CXCL12/*genetics/metabolism; Cohort Studies; Dose-Response Relationship; Drug; Echocardiography; Exercise Tolerance; Female; Follow-Up Studies; Genetic Therapy/*adverse effects/*methods; Heart Failure/metabolism/pathology/*therapy; Humans; Male; Middle Aged; Myocardium/metabolism/pathology; Natriuretic Peptide; Peptide Fragments/blood; Positron-Emission Tomography; Quality of Life; Treatment Outcome

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

816–825

5

112